- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Annual Report on the Status of Cancer in the United States Released
The Annual Report to the Nation on Status of Cancer, product of a collaboration between The American Cancer Society, Centers for Disease Control and Prevention, National Cancer Institute, and North American Association of Central Cancer Registries, has been published.
The Annual Report to the Nation on Status of Cancer, the result of a collaboration between The American Cancer Society, Centers for Disease Control and Prevention, National Cancer Institute, and North American Association of Central Cancer Registries, has been published in the Journal of the National Cancer Institute.
The study provides population-based cancer trends, with a particular focus on breast cancer incidence. The major findigs of the report include:
- An annual 1.8% decrease in cancer incidence in men from 2007 to 2011
- Stable rates of incidence for women between 1998 to 2011
- An annual 0.8% increase in children from 2005 to the present
- A reducing mortality rate among both men and women since the early 1990’s and among children since the 1970’s.
The report presents a detailed analysis of breast cancer incidence and mortality, and draws a correlation with economic strata and race. Read the report here.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2
September 7th 2025Treatment of EGFR-mutated non–small cell lung cancer (NSCLC) is shifting toward next-generation sequencing and combination regimens that improve survival but increase toxicity, requiring individualized care.
Read More
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
